Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan

Hui, Elaine; Bravis, Vassiliki; Salih, Saba Ibrahim; Hassanein, Mohamed; Devendra, Devasenan

doi:10.1111/j.1742-1241.2010.02347.x

Cited by 43 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In another study, switching from premixed insulin formulation (30% regular/70% NPH) to 50 regular/50NPH insulin during the evening meal demonstrated a reduction in HbA1c with less hypoglycemic episodes. 19 The use of insulin pump therapy has been shown to be effective in improving glycemic control and in reducing the risk of hypoglycemia in patients with type 1 diabetes during Ramadan. The use of an insulin pump helps to provide a continuous basal rate of insulin during the fasting period and to rapidly cover for meals intake after the breaking of the fast.…”

Section: Use Of Glucose-lowering Medications During Ramadanmentioning

confidence: 99%

Recommendations for management of diabetes during Ramadan: update 2015

Ibrahim¹,

Magd

Annabi

et al. 2015

BMJ Open Diab Res Care

118

125

View full text Add to dashboard Cite

Since the first ADA working group report on the recommendations for management of diabetes during Ramadan in 2005 and our update in 2010, we received many inquiries asking for regular updates on information regarding education, nutritional habits and new oral and injectable agents that may be useful for the management of patients with diabetes during Ramadan. Patients can be stratified into their risk of hypoglycemia and/or complications prior to the start of the fasting period of Ramadan. Those at high risk of hypoglycemia and with multiple diabetic complications should be advised against prolonged fasting. Even in the lower hypoglycemia risk group, adverse effects may still occur. In order to minimize adverse side effects during fasting in patients with diabetes and improve or maintain glucose control, education and discussion of glucose monitoring and treatment regimens should occur several weeks prior to Ramadan. Agents such as metformin, thiazolidinediones and dipeptidyl peptidase-4 inhibitors appear to be safe and do not need dose adjustment. Most sulfonylureas may not be used safely during Ramadan except with extreme caution; besides, older agents, such as chlorpropamide or glyburide, should not be used. Reduction of the dosage of sulfonylurea is needed depending on the degree of control prior to fasting. Misconceptions and local habits should be addressed and dealt with in any educational intervention and therapeutic planning with patients with diabetes. In this regard, efforts are still needed for controlled prospective studies in the field of efficacy and safety of the different interventions during the Ramadan Fast.

show abstract

Section: Use Of Glucose-lowering Medications During Ramadanmentioning

confidence: 99%

Recommendations for management of diabetes during Ramadan: update 2015

Ibrahim¹,

Magd

Annabi

et al. 2015

BMJ Open Diab Res Care

118

125

View full text Add to dashboard Cite

show abstract

“…Similarly, in another study insulin lispro Mix50 (50% lispro/50% lispro protamine) in the evening and regular human insulin with NPH (30:70) in the morning improved glycaemic control without increasing the incidence of hypoglycaemic events compared with regular human insulin with NPH (30:70) given twice daily [55].…”

Section: Insulin Treatment For T2dmmentioning

confidence: 99%

Diabetes and Ramadan: Practical guidelines

Hassanein

Alarouj

Hamdy

et al. 2017

Diabetes Research and Clinical Practice

275

357

View full text Add to dashboard Cite

“…27 However, the findings of an observational study suggested that using Humalog Mix50 (Lilly) at ifta instead of Mix30 reduced postprandial glucose excursions and reduced hypoglycaemia. 28 We suggest that patients taking twice daily insulin should reduce the suhur dose by 30% if they are well controlled, and consider switching to a Mix 50 preparation if their postprandial glucose remains raised.…”

Section: Premixed Insulinsmentioning

confidence: 99%